8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 9, 2012

BIONOVO, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-33498	20-5526892
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

5858 Horton Street, Suite 400, Emeryville, California	94608
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (510) 601-2000       

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On March 9, 2012, Bionovo, Inc., a Delaware corporation (the “Company”), issued the press release filed as Exhibit 99.1 to this Current Report, the full text of which is incorporated in this Item 8.01 by reference.  

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.
99.1	Press Release of the Company, dated March 9, 2012.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 9, 2012

Bionovo, Inc.

By: ___/s/ Isaac Cohen__________________

Name:  Isaac Cohen

Title: Chairman and Chief Executive

Officer

EXHIBIT INDEX

99.1 Press Release of the Company, dated March 9, 2012.

EX-99.1

Exhibit 99.1

          Company Contact:

David Boyle
Tel: 510.601.2000
investor@bionovo.com

Bionovo Restructures Work Force

Management Compensation Restructured

EMERYVILLE, Calif. – March 9, 2012 -- Bionovo, Inc. (OTC Link Platform: BNVI.PK) today announced that it will need to obtain substantial additional funding to achieve its objectives of internally developing drugs. The Company reduced its workforce by over 90%. The remaining management of the Company will receive reduced cash compensation until either adequate financing can be obtained or the Company is sold. The Company can not make any assurances about either of these events. As previously announced, management and the board of directors are continuing to explore strategic options for the Company. Management is currently reviewing the status of the ongoing clinical trial for Menerba.

The Company does not currently have adequate internal liquidity to meet its cash needs. If sufficient additional funds are not received in the near term, the Company may not be able to execute its business plan and may need to further curtail or cease operations.

AboutBionovo,Inc.

Bionovo,Inc.isapharmaceuticalcompanyfocusedonthediscoveryanddevelopmentofsafeand effectivetreatmentsforwomen'shealthandcancer;marketswithsignificantunmetneedsand billionsinpotentialannualrevenue.TheCompanyappliesitsexpertiseinthebiologyof menopauseandcancertodesignnewdrugsderivedfrombotanicalsourceswhichhavenovel mechanisms ofaction.Basedontheresultsofearlyandmid-stageclinicaltrials,Bionovobelieves theyhavediscoverednewclassesofdrugcandidateswithintheirrichpipelinewiththepotentialto beleadersintheirmarkets.Bionovoisheadquartered inEmeryville,Californiaandistradedon theOTCQBunderthesymbol,"BNVI".FormoreinformationaboutBionovoand itsprograms,visit:http://www.bionovo.com.

ForwardLookingStatements

The statements contained in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the company’s or management’s expectations, hopes, beliefs, intentions, or strategies regarding future developments and their potential effects on the company. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” “hope” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. While the company believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements. There can be no assurance that future developments will be those that the company has anticipated. The forward-looking statements contained in this press release include, but are not limited to, those that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Suchforward-lookingstatementsinvolveknownandunknownrisksuncertainties,including risks and uncertainties relatingtoproductdevelopment,efficacyandsafety, regulatoryactionsordelays,theabilitytoobtainormaintainpatentorotherproprietaryintellectual propertyprotection,marketacceptance, physicianacceptance, thirdpartyreimbursement,future capitalrequirements,competitioningeneralandotherfactorsthatmaycauseactualresultstobe materiallydifferentfromthosedescribedhereinasanticipated,believed,estimatedorexpected. Certainoftheserisks, uncertainties and other factors areorwillbedescribedingreaterdetailinourfilingswith theSecuritiesandExchangeCommission,whichareavailableat http://www.sec.gov. Bionovo,Inc. is providing the information in this press release only as of the date hereof and is undernoobligation(andexpresslydisclaimsanysuchobligation)toupdateoralterits forward-lookingstatementswhetherasaresultofnewinformation,futureeventsorotherwise.